HCM ▼ -3.5% - HUTCHMED (China) Limited
$HCM - HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
28-OCT-2026 08:00 PM ET
Share this post
More filings for $HCM
HCM ▼ -1.0% - HUTCHMED (China) LimitedOct 27, 2026HCM ▲ +0.6% - HUTCHMED (China) LimitedOct 26, 2026HCM ▲ +0.6% - HUTCHMED (China) LimitedOct 26, 2026HCM ▲ +3.9% - HUTCHMED (China) LimitedOct 21, 2026HCM ▲ +0.9% - HUTCHMED (China) LimitedSep 29, 2026HCM ▲ +2.1% - HUTCHMED (China) LimitedSep 24, 2026
View full $HCM filing history →💬 Comments
Loading comments…
Leave a comment